Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committtee and Pediatric Advisory Committee

Agenda

The Committees will discuss the benefit risk assessment of long acting beta-2 adrenergic agonists for the treatment of asthma in adults and children.

Meeting Materials

FDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.  Background material is available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on year 2008 and scroll down to the appropriate advisory committee link.

Public Participation Information

Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

• Written submissions may be made to the contact person on or before November 25, 2008.
• Oral presentations from the public will be scheduled between approximately 9:00 a.m. and 10:00 a.m., December 11. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 10, 2008

Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by November 17, 2008.

Contact Information

• Kristine T. Khuc, Pharm.D., R.Ph.
  Center for Drug Evaluation and Research (HFD-21)
  Food and Drug Administration
  5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093)
  Rockville, MD 20857
  Phone: 301-827-7001
  FAX: 301-827-6776
  Email: kristine.khuc@fda.hhs.gov

• FDA Advisory Committee Information Line
  1-800-741-8138
  (301-443-0572 in the Washington DC area)
  Code: 3014512545 or 3014512535 or 8732310001
  Please call the Information Line for up-to-date information on this meeting

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.  Therefore, you should always check the agency’s Website and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

FDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.  FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs.  If you require special accommodations due to a disability, please contact Kristine Khuc at (301) 827-7001 at least 7 days in advance of the meeting.  FDA is committed to the orderly conduct of its advisory committee meetings. 

Please visit our Web site at http://www.fda.gov/oc/advisory/default.htm for procedures on public conduct during advisory committee meetings.

Advisory Committee Calendar
Advisory Commitee Home Page

Back to Top     Human Drug Advisory Committees

PDF requires the free Adobe Acrobat Reader

Date created: October 24, 2008

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research